Inovio Says Early Covid Vaccine Study Yields Positive Result (1)

Inovio Pharmaceuticals Inc., one of the front-runners in the sprint to come up with a Covid-19 vaccine, said more than 90% of subjects showed an immune response to its experimental shot based on initial data from an early trial.

The U.S. biotech company’s vaccine was also selected to be part of a non-human primate challenge study as part of the government’s Operation Warp Speed, the program aimed at providing substantial quantities of vaccines for Americans by January 2021, according to a statement.

Still, investors are likely to focus on the “paucity of information” in the release, which may ...